Free Trial
→ New “Trump” currency proposed in DC (From Paradigm Press) (Ad) Buy VKTX Stock  Free VKTX Stock Alerts

Viking Therapeutics (VKTX) Financials

Viking Therapeutics logo
$24.57 +2.35 (+10.58%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for Viking Therapeutics

Annual Income Statements for Viking Therapeutics

This table shows Viking Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -23 -15 -21 -22 -26 -79 -55 -69 -86 -110
Consolidated Net Income / (Loss)		 -23 -15 -21 -22 -26 -39 -55 -69 -86 -110
Net Income / (Loss) Continuing Operations		 -23 -15 -21 -22 -26 -79 -55 -69 -86 -110
Total Pre-Tax Income 		-23 -15 -21 -22 -26 -79 -55 -69 -86 -110
Total Operating Income		 -12 -14 -19 -26 -33 -43 -56 -70 -101 -151
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 12 14 19 26 33 85 56 70 101 151
Selling, General & Admin Expense		 5.03 4.85 5.33 7.12 9.13 11 11 16 37 49
Research & Development Expense		 6.97 9.00 14 19 24 32 45 54 64 102
Amortization Expense		 - - - - - - 0.02 0.06 0.09 0.09
Total Other Income / (Expense), net		 -11 -0.88 -1.51 4.10 6.91 6.33 0.71 1.55 15 41
Interest & Investment Income		 -0.09 -0.02 0.00 3.24 7.05 3.23 0.70 1.59 15 41
Other Income / (Expense), net		 -10 0.93 -0.23 1.27 -0.15 3.10 0.01 -0.04 0.00 0.11
Basic Earnings per Share		 ($3.68) ($0.90) ($0.79) ($0.38) ($0.36) ($0.54) ($0.71) ($0.90) ($0.91) ($1.01)
Weighted Average Basic Shares Outstanding		 6.36M 16.28M 25.98M 57.58M 71.96M 72.60M 77.20M 76.83M 94.35M 109.04M
Diluted Earnings per Share		 ($3.68) ($0.90) ($0.79) ($0.38) ($0.36) ($0.54) ($0.71) ($0.90) ($0.91) ($1.01)
Weighted Average Diluted Shares Outstanding		 6.36M 16.28M 25.98M 57.58M 71.96M 72.60M 77.20M 76.83M 94.35M 109.04M
Weighted Average Basic & Diluted Shares Outstanding		 6.36M 16.28M 25.98M 57.58M 71.96M 72.60M 77.20M 78.42M 100.49M 112.25M

Quarterly Income Statements for Viking Therapeutics

This table shows Viking Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -16 -20 -20 -19 -23 -25 -27 -22 -25 -35
Consolidated Net Income / (Loss)		 -16 -20 -20 -19 -23 -25 -27 -22 -25 -35
Net Income / (Loss) Continuing Operations		 -16 -20 -20 -19 -23 -25 -27 -22 -25 -35
Total Pre-Tax Income 		-16 -20 -20 -19 -23 -25 -27 -22 -25 -35
Total Operating Income		 -16 -20 -21 -24 -27 -29 -34 -34 -37 -46
Total Operating Expenses		 16 20 21 24 27 29 34 34 37 46
Selling, General & Admin Expense		 4.24 4.11 9.53 9.82 8.89 8.78 9.97 10 14 15
Research & Development Expense		 12 16 11 14 18 21 24 24 23 31
Total Other Income / (Expense), net		 0.45 0.59 1.03 4.52 4.73 4.74 6.75 12 12 11
Interest & Investment Income		 0.45 0.73 1.03 4.55 4.73 4.71 6.75 12 12 11
Other Income / (Expense), net		 0.00 -0.14 0.00 -0.03 0.00 0.03 0.00 -0.02 0.11 0.02
Basic Earnings per Share		 ($0.21) ($0.25) ($0.25) ($0.19) ($0.23) ($0.24) ($0.26) ($0.20) ($0.22) ($0.33)
Weighted Average Basic Shares Outstanding		 76.51M 76.83M 78.35M 99.01M 99.85M 94.35M 103.46M 110.39M 110.91M 109.04M
Diluted Earnings per Share		 ($0.21) ($0.25) ($0.25) ($0.19) ($0.23) ($0.24) ($0.26) ($0.20) ($0.22) ($0.33)
Weighted Average Diluted Shares Outstanding		 76.51M 76.83M 78.35M 99.01M 99.85M 94.35M 103.46M 110.39M 110.91M 109.04M
Weighted Average Basic & Diluted Shares Outstanding		 76.69M 78.42M 99.58M 100.03M 100.03M 100.49M 110.27M 110.80M 111.44M 112.25M

Annual Cash Flow Statements for Viking Therapeutics

This table details how cash moves in and out of Viking Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 0.01 2.31 5.91 7.40 -16 21 -2.75 11 19 -29
Net Cash From Operating Activities		 -8.73 -11 -15 -19 -25 -22 -48 -48 -73 -88
Net Cash From Continuing Operating Activities		 -8.73 -11 -15 -19 -25 -22 -48 -48 -73 -88
Net Income / (Loss) Continuing Operations		 -23 -15 -21 -22 -26 -39 -55 -69 -86 -110
Consolidated Net Income / (Loss)		 -23 -15 -21 -22 -26 -39 -55 -69 -86 -110
Amortization Expense		 1.03 2.08 2.94 1.26 1.02 4.19 4.22 1.57 -7.82 -17
Non-Cash Adjustments To Reconcile Net Income		 13 0.73 1.11 1.21 5.49 8.40 7.29 9.37 17 31
Changes in Operating Assets and Liabilities, net		 0.62 0.85 1.77 0.82 -5.49 5.13 -4.10 9.58 3.23 8.16
Net Cash From Investing Activities		 -13 3.03 -1.73 -266 7.46 42 38 55 -179 -553
Net Cash From Continuing Investing Activities		 -13 3.03 -1.73 -266 7.46 42 38 55 -179 -553
Purchase of Investments		 -16 -17 -23 -348 -362 -281 -168 -121 -478 -1,113
Sale and/or Maturity of Investments		 2.56 20 21 82 370 322 206 176 299 560
Net Cash From Financing Activities		 22 10 22 300 0.89 0.95 6.88 4.16 271 612
Net Cash From Continuing Financing Activities		 22 10 22 292 0.89 0.95 6.88 4.16 271 612
Repurchase of Common Equity		 -2.78 -1.10 -0.50 - -0.07 -0.03 0.00 -6.80 0.00 0.00
Issuance of Common Equity		 25 12 23 297 1.11 1.27 7.63 0.85 6.77 11
Other Financing Activities, net		 -0.42 -0.03 -0.02 0.13 -0.15 -0.30 -0.75 10 265 602

Quarterly Cash Flow Statements for Viking Therapeutics

This table details how cash moves in and out of Viking Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 13 7.08 -18 51 -32 18 140 -152 6.46 -24
Net Cash From Operating Activities		 -13 -11 -25 -11 -20 -18 -6.13 -29 -22 -31
Net Cash From Continuing Operating Activities		 -13 -11 -25 -11 -20 -18 -6.13 -29 -22 -31
Net Income / (Loss) Continuing Operations		 -16 -20 -20 -19 -23 -25 -27 -22 -25 -35
Consolidated Net Income / (Loss)		 -16 -20 -20 -19 -23 -25 -27 -22 -25 -35
Amortization Expense		 0.31 0.03 -0.29 -1.86 -3.07 -2.60 -2.72 -5.34 -4.87 -3.90
Non-Cash Adjustments To Reconcile Net Income		 2.12 2.28 3.82 4.56 4.74 3.99 8.65 6.93 10 5.03
Changes in Operating Assets and Liabilities, net		 -0.15 6.37 -8.65 5.09 1.21 5.58 15 -7.86 -2.38 3.10
Net Cash From Investing Activities		 27 7.26 2.20 -204 -13 36 -460 -126 26 6.58
Net Cash From Continuing Investing Activities		 27 7.26 2.20 -204 -13 36 -460 -126 26 6.58
Purchase of Investments		 -10 -45 -57 -244 -79 -98 -597 -230 -150 -137
Sale and/or Maturity of Investments		 37 52 60 39 67 133 137 104 176 144
Net Cash From Financing Activities		 0.01 11 4.18 267 -0.07 0.19 606 2.91 2.52 1.00
Net Cash From Continuing Financing Activities		 0.01 11 4.18 267 -0.07 0.19 606 2.91 2.52 1.00
Issuance of Common Equity		 - 0.15 - - -0.00 0.19 - - 2.52 1.00

Annual Balance Sheets for Viking Therapeutics

This table presents Viking Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets		 15 15 22 302 284 257 211 169 368 908
Total Current Assets		 15 14 22 302 284 256 211 167 367 907
Cash & Equivalents		 0.77 3.08 8.99 25 8.38 29 26 37 56 27
Short-Term Investments		 13 10 12 277 267 219 176 119 307 876
Prepaid Expenses		 1.10 0.82 1.28 0.61 7.86 7.72 8.43 12 5.15 1.13
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.24 0.56 0.27 0.18 0.76 0.40 0.13 1.49 1.16 1.05
Other Noncurrent Operating Assets		 0.24 0.56 0.27 0.18 0.76 0.40 0.13 1.49 1.16 1.05
Total Liabilities & Shareholders' Equity		 15 15 22 302 284 257 211 169 368 908
Total Liabilities		 6.71 6.49 8.66 4.56 7.14 12 8.78 23 20 28
Total Current Liabilities		 1.98 6.48 8.66 4.55 6.78 12 8.78 22 19 27
Accounts Payable		 0.59 1.20 1.53 0.96 2.43 3.99 1.44 8.53 7.51 9.81
Accrued Expenses		 1.38 1.24 2.26 3.59 4.04 7.81 7.31 13 11 17
Other Current Liabilities		 0.00 0.73 1.40 - 0.30 0.33 0.03 0.30 0.32 0.49
Total Noncurrent Liabilities		 4.74 0.02 0.00 0.01 0.36 0.06 0.00 1.26 0.94 0.63
Other Noncurrent Operating Liabilities		 2.55 - - - 0.36 0.03 0.00 1.26 0.94 0.63
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 8.72 8.04 13 298 277 244 202 145 348 880
Total Preferred & Common Equity		 8.72 8.04 13 298 277 244 202 145 348 880
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 8.72 8.04 13 298 277 244 202 145 349 881
Common Stock		 54 68 94 401 406 413 426 445 734 1,369
Retained Earnings		 -46 -60 -81 -103 -129 -168 -223 -292 -378 -488
Treasury Stock		 - - - - - - 0.00 -6.80 -6.80 0.00

Quarterly Balance Sheets for Viking Therapeutics

This table presents Viking Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 167 151 401 383 968 947 938
Total Current Assets		 165 149 399 381 966 946 937
Cash & Equivalents		 29 18 70 37 196 44 50
Short-Term Investments		 126 117 323 339 767 898 880
Prepaid Expenses		 10 3.93 6.45 5.06 0.64 0.14 6.21
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 1.54 1.38 1.32 1.36 1.09 1.01 1.16
Other Noncurrent Operating Assets		 1.54 1.38 1.32 1.36 1.09 1.01 1.16
Total Liabilities & Shareholders' Equity		 167 151 401 383 968 947 938
Total Liabilities		 15 17 15 14 34 26 26
Total Current Liabilities		 14 16 13 13 33 25 26
Accounts Payable		 3.14 3.80 5.61 5.71 5.23 11 0.25
Accrued Expenses		 11 12 7.55 7.38 27 14 25
Other Current Liabilities		 0.30 0.31 0.31 0.32 0.33 0.33 0.48
Total Noncurrent Liabilities		 1.34 1.18 1.10 1.02 0.85 0.77 0.76
Other Noncurrent Operating Liabilities		 1.34 1.18 1.10 1.02 0.85 0.77 0.76
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 151 134 386 368 934 921 911
Total Preferred & Common Equity		 151 134 386 368 934 921 911
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 151 135 386 368 935 923 910
Common Stock		 432 453 725 729 1,341 1,351 1,362
Retained Earnings		 -272 -312 -331 -353 -405 -428 -452
Treasury Stock		 -6.80 -6.80 -6.80 -6.80 0.00 0.00 0.00

Annual Metrics and Ratios for Viking Therapeutics

This table displays calculated financial ratios and metrics derived from Viking Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -3.38% 49.33% -50.84% -44.51% -34.61% -11.19% -45.48% -33.77% -57.85% -54.29%
EBIT Growth		 -5.49% 42.37% -49.33% -29.02% -31.89% -20.49% -40.73% -26.44% -43.23% -49.57%
NOPAT Growth		 48.88% -15.43% -37.72% -37.18% -24.95% -30.52% -30.52% -26.35% -43.31% -49.68%
Net Income Growth		 -6.94% 37.05% -39.68% -7.22% -16.84% -53.21% -39.23% -25.24% -24.73% -28.02%
EPS Growth		 29.64% 75.54% 12.22% 51.90% 5.26% -50.00% -31.48% -26.76% -1.11% -10.99%
Operating Cash Flow Growth		 -448.66% -26.80% -33.30% -27.08% -31.98% 12.02% -118.51% -1.70% -51.61% -19.64%
Free Cash Flow Firm Growth		 0.00% 61.23% -3.57% -57.90% -54.74% 13.48% -75.84% 8.17% -70.40% -39.67%
Invested Capital Growth		 86.27% 44.13% -101.75% -3.63% 139.28% -372.92% 94.58% -4,540.64% -35.45% -87.90%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -35.32% 14.80% -3.31% -18.43% -4.95% 23.55% -38.64% -14.28% -11.79% -12.22%
EBIT Q/Q Growth		 -33.25% 11.18% -3.31% -15.02% -5.93% 20.38% -33.12% -12.43% -9.60% -12.68%
NOPAT Q/Q Growth		 -55.20% 5.99% -3.75% -11.09% -5.95% 14.87% -24.86% -12.42% -9.80% -12.65%
Net Income Q/Q Growth		 -38.29% 8.94% -2.19% -5.52% -9.38% -9.72% -2.63% -11.68% -6.24% -10.90%
EPS Q/Q Growth		 -36.80% 40.00% -6.76% 19.15% -20.00% -10.20% 0.00% -12.50% 1.09% -9.78%
Operating Cash Flow Q/Q Growth		 -48.67% 7.01% -11.16% 6.33% -57.78% 22.32% -16.86% 2.86% -10.07% -18.24%
Free Cash Flow Firm Q/Q Growth		 0.00% -1.83% -15.21% 3.29% -47.10% 36.20% -44.05% 8.77% -11.60% -13.10%
Invested Capital Q/Q Growth		 -49.72% -16.37% 17.74% -78.76% 132.34% -167.51% 92.73% -171.88% -72.05% -35.62%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 50.00% 100.03% 100.09% 100.10% 100.09%
Interest Burden Percent		 104.38% 114.01% 106.64% 88.62% 78.52% 199.67% 98.74% 97.74% 85.10% 72.85%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 349.22% -175.71% -191.36% -14.18% -8.97% -15.15% -24.65% -39.67% -34.79% -17.90%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -1,899.52% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 349.22% -175.71% -191.36% -14.18% -8.97% -15.15% -24.65% -39.67% -34.82% -17.92%
Return on Equity Simple (ROE_SIMPLE)		 -268.24% -183.17% -152.84% -7.41% -9.30% -16.16% -27.24% -47.39% -24.65% -12.49%
Net Operating Profit after Tax (NOPAT)		 -8.40 -9.69 -13 -18 -23 -30 -39 -49 -71 -106
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -225.13% -46.23% -53.65% -2.35% -1.00% -3.68% -7.11% -10.97% -5.92% -0.68%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -33.89% -20.26% -12.00%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -22 -13 -19 -25 -33 -40 -56 -70 -101 -151
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -21 -11 -16 -24 -32 -35 -51 -69 -109 -168
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 3.78 2.98 8.59 1.84 2.09 1.68 1.78 4.96 5.34 5.09
Price to Tangible Book Value (P/TBV)		 3.78 2.98 8.59 1.84 2.09 1.68 1.78 4.96 5.34 5.09
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 205.21 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.25 0.41 0.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.99 -1.30 -1.25 -1.02 -1.00 -1.00 -1.01 -1.03 -1.05 -1.03
Leverage Ratio		 -1.38 1.79 1.70 1.04 1.02 1.04 1.05 1.09 1.09 1.04
Compound Leverage Factor		 -1.44 2.04 1.82 0.92 0.80 2.07 1.03 1.07 0.93 0.76
Debt to Total Capital		 19.78% 28.90% 20.40% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 28.90% 20.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 19.78% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 80.22% 71.10% 79.60% 100.00% 100.00% 99.99% 100.00% 100.00% 100.11% 100.09%
Debt to EBITDA		 -0.10 -0.30 -0.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.56 0.91 1.05 0.00 0.00 7.02 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.26 -0.34 -0.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 1.42 1.02 1.28 0.00 0.00 8.32 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -4.95 -5.90 0.74 72.33 48.88 19.98 23.39 15.87 54.44 95.81
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.08% -0.10%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 7.69 2.16 2.52 66.40 41.83 21.12 23.98 7.61 19.19 33.09
Quick Ratio		 7.13 2.03 2.38 66.27 40.67 20.48 23.02 7.08 18.92 32.93
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -29 -11 -12 -18 -28 -24 -43 -39 -67 -94
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -32.10 -6.22 -8.97 -45.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -9.77 -6.19 -11.50 -46.42 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -9.77 -6.19 -11.50 -46.42 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -3.23 -1.80 -3.64 -3.77 1.48 -4.04 -0.22 -10 -14 -26
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 20 1.42 -1.83 -0.13 5.25 -5.52 3.82 -9.94 -3.60 -12
Enterprise Value (EV)		 21 14 99 245 304 162 158 565 1,499 3,582
Market Capitalization		 33 24 116 547 580 411 360 721 1,862 4,484
Book Value per Share		 $0.90 $0.40 $0.47 $4.17 $3.83 $3.35 $2.58 $1.90 $3.49 $7.91
Tangible Book Value per Share		 $0.90 $0.40 $0.47 $4.17 $3.83 $3.35 $2.58 $1.90 $3.49 $7.91
Total Capital		 11 11 17 298 277 244 202 145 348 880
Total Debt		 2.15 3.27 3.45 0.00 0.00 0.03 0.00 0.00 0.00 0.00
Total Long-Term Debt		 2.15 0.00 0.00 0.00 0.00 0.03 0.00 0.00 0.00 0.00
Net Debt		 -12 -9.88 -17 -302 -276 -248 -202 -155 -362 -903
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.88 -2.38 -3.93 -3.94 1.09 -4.41 -0.35 -10 -14 -23
Debt-free Net Working Capital (DFNWC)		 13 11 17 298 277 244 202 145 348 880
Net Working Capital (NWC)		 13 7.50 13 298 277 244 202 145 348 880
Net Nonoperating Expense (NNE)		 15 5.04 7.23 3.75 2.90 9.63 16 20 15 4.32
Net Nonoperating Obligations (NNO)		 -12 -9.85 -17 -302 -276 -248 -202 -155 -362 -906
Total Depreciation and Amortization (D&A)		 1.03 2.08 2.94 1.26 1.02 4.19 4.22 1.57 -7.82 -17
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.68) ($0.90) ($0.79) ($0.38) ($0.36) ($0.54) ($0.71) ($0.90) ($0.91) ($1.01)
Adjusted Weighted Average Basic Shares Outstanding		 9.68M 23.83M 50.90M 71.99M 72.56M 74.13M 78.36M 76.83M 94.35M 109.04M
Adjusted Diluted Earnings per Share		 ($3.68) ($0.90) ($0.79) ($0.38) ($0.36) ($0.54) ($0.71) ($0.90) ($0.91) ($1.01)
Adjusted Weighted Average Diluted Shares Outstanding		 9.68M 23.83M 50.90M 71.99M 72.56M 74.13M 78.36M 76.83M 94.35M 109.04M
Adjusted Basic & Diluted Earnings per Share		 ($3.68) ($0.90) ($0.79) ($0.38) ($0.36) ($0.54) ($0.71) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 6.36M 16.28M 25.98M 57.58M 71.96M 72.60M 77.20M 78.42M 100.49M 112.25M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.40 -9.69 -13 -18 -23 -30 -39 -49 -71 -106
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -25.09 -7.23 -15.04 -61.62 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -9.40 -5.42 -10.40 -45.33 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -25.09 -7.23 -15.04 -61.62 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -9.40 -5.42 -10.40 -45.33 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -11.89% -7.44% -2.43% 0.00% -0.28% -0.07% 0.00% -9.87% 0.00% 0.00%

Quarterly Metrics and Ratios for Viking Therapeutics

This table displays calculated financial ratios and metrics derived from Viking Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -29.87% -72.88% -35.73% -48.99% -90.98% -56.17% -76.66% -53.76% -36.20% -57.33%
EBIT Growth		 -22.30% -61.56% -27.54% -34.51% -68.34% -43.22% -65.91% -43.32% -33.68% -58.00%
NOPAT Growth		 -20.84% -62.13% -26.42% -34.65% -68.34% -44.38% -65.91% -43.45% -34.08% -57.89%
Net Income Growth		 -19.10% -58.30% -21.29% -10.29% -42.86% -25.80% -40.06% -15.73% -10.68% -43.94%
EPS Growth		 -23.53% -66.67% -19.05% 17.39% -9.52% 4.00% -4.00% -5.26% 4.35% -37.50%
Operating Cash Flow Growth		 -23.55% 11.53% -134.03% 14.93% -45.63% -61.45% 75.11% -149.35% -11.72% -76.76%
Free Cash Flow Firm Growth		 -34.70% 66.18% 58.48% -13.08% -39.66% -297.18% 36.53% 56.06% 2.05% -19.95%
Invested Capital Growth		 -24.02% -4,540.64% -338.38% -84.57% -114.04% -35.45% -176.77% -263.13% -138.37% -87.90%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 7.67% -28.42% -2.10% -23.08% -18.34% -5.01% -15.50% -7.12% -4.83% -21.30%
EBIT Q/Q Growth		 8.36% -26.11% -0.55% -15.75% -14.69% -7.29% -16.48% 0.01% -6.98% -26.81%
NOPAT Q/Q Growth		 8.14% -25.23% -1.25% -15.60% -14.85% -7.41% -16.35% 0.06% -7.35% -26.49%
Net Income Q/Q Growth		 9.52% -24.00% 0.14% 1.57% -17.21% -9.19% -11.18% 18.67% -12.09% -42.01%
EPS Q/Q Growth		 8.70% -19.05% 0.00% 24.00% -21.05% -4.35% -8.33% 23.08% -10.00% -50.00%
Operating Cash Flow Q/Q Growth		 -0.42% 19.06% -125.54% 53.60% -71.91% 10.27% 65.23% -364.84% 22.98% -41.98%
Free Cash Flow Firm Q/Q Growth		 11.10% 59.92% -28.81% -146.35% -9.80% -13.99% 75.63% -70.55% -144.75% -39.59%
Invested Capital Q/Q Growth		 -1.38% -171.88% -13.40% 40.95% -17.58% -72.05% -94.62% 22.53% 22.82% -35.62%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.17% 99.32% 100.14% 100.00% 100.01% 100.24% 100.10% 100.00% 100.10% 100.12%
Interest Burden Percent		 97.22% 96.42% 94.97% 80.87% 82.64% 83.91% 80.20% 65.31% 68.36% 76.54%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -33.84% -39.67% -45.71% -26.88% -31.12% -34.79% -17.55% -14.80% -15.50% -17.90%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -33.84% -39.67% -45.80% -26.88% -31.12% -34.82% -17.59% -14.83% -15.48% -17.92%
Return on Equity Simple (ROE_SIMPLE)		 -40.76% 0.00% -53.93% -19.19% -21.96% 0.00% -10.04% -10.50% -10.88% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -14 -14 -17 -19 -20 -24 -24 -26 -32
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.39% -3.00% -3.12% -0.93% -1.30% -1.59% -0.63% 0.24% 0.10% -0.48%
Return On Investment Capital (ROIC_SIMPLE)		 - -9.77% - - - -5.88% - - - -3.68%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -16 -20 -21 -24 -27 -29 -34 -34 -36 -46
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -16 -20 -21 -26 -30 -32 -37 -39 -41 -50
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.38 4.96 9.69 4.18 3.01 5.34 8.77 6.33 7.71 5.09
Price to Tangible Book Value (P/TBV)		 1.38 4.96 9.69 4.18 3.01 5.34 8.77 6.33 7.71 5.09
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.03 -1.04 -1.02 -1.02 -1.05 -1.04 -1.02 -1.02 -1.03
Leverage Ratio		 1.07 1.09 1.09 1.06 1.06 1.09 1.05 1.03 1.03 1.04
Compound Leverage Factor		 1.04 1.05 1.04 0.85 0.87 0.91 0.84 0.67 0.71 0.80
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.46% 100.00% 100.00% 100.11% 100.17% 100.25% 99.82% 100.09%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 6.61 16.84 44.27 66.24 45.69 55.08 146.81 136.04 159.54 96.19
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% -0.20% 0.00% 0.00% -0.08% -0.21% -0.17% 0.13% -0.10%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 11.75 7.61 9.55 29.63 28.44 19.19 29.48 37.69 36.47 33.09
Quick Ratio		 11.03 7.08 8.67 29.15 28.07 18.92 29.38 37.55 36.23 32.93
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -11 -4.25 -5.48 -14 -15 -17 -3.48 -5.93 -15 -20
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -3.74 -10 -12 -6.81 -8.00 -14 -32 -25 -19 -26
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.72 -9.94 -8.90 -3.12 -4.26 -3.60 -20 -18 -11 -12
Enterprise Value (EV)		 54 565 1,170 1,221 731 1,499 7,239 4,903 6,084 3,582
Market Capitalization		 209 721 1,306 1,614 1,107 1,862 8,202 5,845 7,015 4,484
Book Value per Share		 $1.97 $1.90 $1.72 $3.88 $3.68 $3.49 $9.04 $8.37 $8.21 $7.91
Tangible Book Value per Share		 $1.97 $1.90 $1.72 $3.88 $3.68 $3.49 $9.04 $8.37 $8.21 $7.91
Total Capital		 151 145 134 386 368 348 934 921 911 880
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -155 -155 -136 -393 -376 -362 -963 -942 -930 -903
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.94 -10 -1.85 -7.03 -8.35 -14 -29 -22 -19 -23
Debt-free Net Working Capital (DFNWC)		 151 145 134 386 368 348 934 921 911 880
Net Working Capital (NWC)		 151 145 134 386 368 348 934 921 911 880
Net Nonoperating Expense (NNE)		 4.44 5.36 5.16 2.61 3.45 4.11 3.50 -1.59 -0.65 3.05
Net Nonoperating Obligations (NNO)		 -155 -155 -146 -393 -376 -362 -966 -946 -931 -906
Total Depreciation and Amortization (D&A)		 0.31 0.03 -0.29 -1.86 -3.07 -2.60 -2.72 -5.34 -4.87 -3.90
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.21) ($0.25) ($0.25) ($0.19) ($0.23) ($0.24) ($0.26) ($0.20) ($0.22) ($0.33)
Adjusted Weighted Average Basic Shares Outstanding		 76.51M 76.83M 78.35M 99.01M 99.85M 94.35M 103.46M 110.39M 110.91M 109.04M
Adjusted Diluted Earnings per Share		 ($0.21) ($0.25) ($0.25) ($0.19) ($0.23) ($0.24) ($0.26) ($0.20) ($0.22) ($0.33)
Adjusted Weighted Average Diluted Shares Outstanding		 76.51M 76.83M 78.35M 99.01M 99.85M 94.35M 103.46M 110.39M 110.91M 109.04M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 76.69M 78.42M 99.58M 100.03M 100.03M 100.49M 110.27M 110.80M 111.44M 112.25M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -14 -14 -17 -19 -20 -24 -24 -26 -32
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -11.02% -9.87% -2.32% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Viking Therapeutics' Financials

When does Viking Therapeutics's financial year end?

According to the most recent income statement we have on file, Viking Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Viking Therapeutics' net income changed over the last 9 years?

Viking Therapeutics' net income appears to be on an upward trend, with a most recent value of -$109.96 million in 2024, rising from -$23.40 million in 2015. The previous period was -$85.90 million in 2023.

What is Viking Therapeutics's operating income?
Viking Therapeutics's total operating income in 2024 was -$150.92 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $151.02 million
How has Viking Therapeutics revenue changed over the last 9 years?

Over the last 9 years, Viking Therapeutics' total revenue changed from $0.00 in 2015 to $0.00 in 2024, a change of 0.0%.

How much debt does Viking Therapeutics have?

Viking Therapeutics' total liabilities were at $28.04 million at the end of 2024, a 39.7% increase from 2023, and a 317.7% increase since 2015.

How much cash does Viking Therapeutics have?

In the past 9 years, Viking Therapeutics' cash and equivalents has ranged from $768.55 thousand in 2015 to $55.52 million in 2023, and is currently $26.68 million as of their latest financial filing in 2024.

How has Viking Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, Viking Therapeutics' book value per share changed from 0.90 in 2015 to 7.91 in 2024, a change of 777.0%.

Remove Ads

Related Companies

This page (NASDAQ:VKTX) was last updated on 4/14/2025 by MarketBeat.com Staff
From Our Partners
The biggest story CNBC isn't talking about (yet)
This Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...
Stansberry Research | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...
Altimetry | Sponsored
If Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?
Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...
Colonial Metals | Sponsored
BITCOIN
Did you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....
Awesomely, LLC | Sponsored
Elon Musk is helping print “new gold”
MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...
True Market Insiders | Sponsored
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...
American Alternative | Sponsored
DeFi Coin on Verge of Breakout!
Crypto’s down — but the fundamentals aren’t. Strategic investors are using this dip to scoop up undervalued...
Crypto 101 Media | Sponsored